0001811468-23-000002.txt : 20231002
0001811468-23-000002.hdr.sgml : 20231002
20231002112441
ACCESSION NUMBER: 0001811468-23-000002
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20231002
DATE AS OF CHANGE: 20231002
EFFECTIVENESS DATE: 20231002
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Atsena Therapeutics, Inc.
CENTRAL INDEX KEY: 0001811468
IRS NUMBER: 845181493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-493532
FILM NUMBER: 231298406
BUSINESS ADDRESS:
STREET 1: 8 DAVIS DRIVE, SUITE 300
CITY: DURHAM
STATE: NC
ZIP: 27709
BUSINESS PHONE: 984-261-2001
MAIL ADDRESS:
STREET 1: 8 DAVIS DRIVE, SUITE 300
CITY: DURHAM
STATE: NC
ZIP: 27709
D
1
primary_doc.xml
X0708
D
LIVE
0001811468
Atsena Therapeutics, Inc.
8 DAVIS DRIVE, SUITE 300
DURHAM
NC
NORTH CAROLINA
27709
984-261-2001
DELAWARE
VectorEyes Therapeutics, Inc.
None
Corporation
true
2019
Patrick
Ritschel
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Executive Officer
Director
Michael
Dial
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Director
Jacqueline
Grant
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Director
Shannon
Boye
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Director
Christina
Isacson
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Director
James
Healy
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Director
Jennifer
Wellman
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Director
Elizabeth
Leiderman
c/o Atsena Therapeutics, Inc.
8 Davis Drive, Suite 300
Durham
NC
NORTH CAROLINA
27709
Executive Officer
Biotechnology
Decline to Disclose
- 06b
false
2023-08-28
false
true
false
0
32000000
24474387
7525613
false
10
0
0
0
false
Atsena Therapeutics, Inc.
/s/ Patrick Ritschel
Patrick Ritschel
Chief Executive Officer
2023-10-02